ARCHIVES

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: CT Scanning Reduced Morbidity, Mortality, Helps Deliver Optimal Treatment, Consensus Panel Says

November 27, 1981

NCI Study Fails To Support Finding Of Excess Cancer In Utah Nuclear Fallout Areas

January 23, 1987

FDA Gives Accelerated Approval To Tykerb For Metastatic Breast Cancer

February 5, 2010

In Appropriations Hearings, Groups Seek NCI Bypass Budget, Differ On CDC Funding.

April 14, 2000

Obey Questions NCI honesty, Transfers IARC Monograph Support To NIH

October 15, 1982

Leter: Payers Must Determine Appropriate Therapies

July 19, 1996